1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hepatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016


DelveInsight’s Report, “Hepatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Hepatitis Report is to understand the market and pipeline status of the drugs around the Hepatitis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Hepatitis. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Hepatitis.
- A review of the marketed products under prescription for Hepatitis, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Hepatitis with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Hepatitis drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Hepatitis drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Hepatitis drugs.
- Coverage of Hepatitis Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Hepatitis key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Hepatitis.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Hepatitis.
- API intelligence over marketed drugs forHepatitisand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Hepatitis.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Hepatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Illustrative Table of contents
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Hepatitis
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Hepatitis
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Hepatitis
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables

- Hepatitis Therapeutic Market, US, Marketed Drugs by Application Type, 2016
- Hepatitis Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
- Hepatitis Therapeutic Market, US, (Year), 2016
- Hepatitis Marketed Drugs, API Manufacturers by US DMF Status, 2016
- Hepatitis Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Hepatitis Drugs, API Manufacturers, Europe by Country, 2016
- Hepatitis Drugs, API Manufacturers, India by State, 2016
- Hepatitis Drugs, API Manufacturers, China by Province, 2016
- Hepatitis Drugs, API Manufacturers by Geography 2016
- Hepatitis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Hepatitis Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2016
- Phase III Drugs for Hepatitis, 2016
- Discontinued Drugs for Hepatitis, 2016

List of Figures

- Hepatitis Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
- Hepatitis Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
- Hepatitis Therapeutic Market, US, (Year), 2016
- Hepatitis Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
- Hepatitis Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Hepatitis Drugs, API Manufacturers, Europe by Country, 2016
- Hepatitis Drugs, API Manufacturers, India by State, 2016
- Hepatitis Drugs, API Manufacturers, China by Province, 2016
- Hepatitis Drugs, API Manufacturers by Geography 2016
- Hepatitis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Hepatitis Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
World Blood Typing, Grouping and Infectious Disease NAT Screening Market: Sales and Market Shares of Major Suppliers by Test and Country

World Blood Typing, Grouping and Infectious Disease NAT Screening Market: Sales and Market Shares of Major Suppliers by Test and Country

  • $ 5450
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report from VPGMarketResearch provides sales and market share estimates for major suppliers of blood typing, grouping and infectious disease screening products by test and country. The report ...

Hepatitis Viruses Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Hepatitis Viruses Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Hepatitis Viruses Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Hepatitis Viruses Diagnostic Tests - Medical Devices Pipeline Assessment, ...

2016-2021  Emerging Italian Diagnostics Market: Instrument and Reagent Supplier Shares by Test, Business Environment, Market Structure

2016-2021 Emerging Italian Diagnostics Market: Instrument and Reagent Supplier Shares by Test, Business Environment, Market Structure

  • $ 3900
  • Industry report
  • November 2016
  • by Venture Planning Group

This new report from VPGMarketResearch.com provides an overview of the Italian diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test ...


Download Unlimited Documents from Trusted Public Sources

Public Health Industry in the UK

  • December 2016
    156 pages
  • Public Health  

    Neurological Di...  

    Hospital  

  • United Kingdom  

View report >

Infectious Disease Statistics in the US

  • December 2016
    32 pages
  • Infectious Dise...  

    Asthma  

  • United States  

View report >

Eye Disease Statistics in the UK

  • December 2016
    9 pages
  • Eye Disease  

    Ophthalmology  

  • United Kingdom  

View report >

Related Market Segments :

Hepatitis
Cloud Computing

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.